STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

SUPN Form 144 shows 59,900-share sale after option exercise

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Supernus Pharmaceuticals (SUPN) notice reports a proposed sale of 59,900 common shares, with an aggregate market value of $2,875,200, to be sold on or about 10/09/2025 through Morgan Stanley Smith Barney LLC on NASDAQ. The shares were acquired the same day by exercise of stock options and paid in cash. The filer also disclosed multiple prior 10b5-1 plan sales across August–October 2025 totaling substantial proceeds (individual trades range from $45,001 to $2,558,888.12), showing ongoing systematic insider selling. The filer affirms no undisclosed material nonpublic information and provides standard Rule 144 representations.

Positive

  • Securities acquired by exercise of options and paid in cash, indicating no contingent consideration
  • Sales executed under 10b5-1 plans, which are pre‑arranged and reduce timing uncertainty about insider intent

Negative

  • Substantial recent insider sales across Aug–Oct 2025 with large gross proceeds (multiple trades above $1M)
  • Proposed sale on 10/09/2025 adds incremental supply equal to 59,900 shares (~0.11% of outstanding), potentially pressuring short-term liquidity

Insights

TL;DR: A near-term insider sale of 59,900 shares follows option exercise and ongoing 10b5-1 sales.

The transaction shows the filer exercised options 10/09/2025 and intends to sell 59,900 shares through Morgan Stanley, generating an indicated market value of $2,875,200. The filing lists many 10b5-1 sales from 08/06/2025 through 10/02/2025, with individual gross proceeds up to $2.56M.

This pattern indicates planned liquidity events rather than ad-hoc disposals; monitor near-term total insider sell volume relative to the company’s outstanding shares (56,073,088) over the next few weeks for potential market supply effects.

TL;DR: The sale size is modest relative to shares outstanding but could add short-term supply pressure on trading days around 10/09/2025.

The proposed sale equals roughly 0.11% of the disclosed 56,073,088 shares outstanding, which is small in isolation. However, cumulative 10b5-1 sales listed (multiple trades across months) represent larger absolute proceeds and could affect intraday liquidity on sales dates.

Watch trading volume on 10/09/2025 and nearby sessions to see if the disclosed sales coincide with higher-than-normal supply; such effects typically appear within days of executed filings.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What did the SUPN Form 144 disclose about the 10/09/2025 sale?

It discloses a proposed sale of 59,900 common shares with an aggregate market value of $2,875,200, acquired by option exercise on 10/09/2025 and to be sold through Morgan Stanley Smith Barney LLC on NASDAQ.

Were the shares purchased or paid for on the same day in the SUPN filing?

Yes. The table shows the shares were acquired on 10/09/2025 by exercise of stock options and paid in cash on the same date.

Does the filing show prior insider sales for SUPN this year?

Yes. Multiple 10b5-1 sales are listed from 08/06/2025 through 10/02/2025, with individual gross proceeds ranging up to $2,558,888.12.

How large is the proposed sale relative to SUPN shares outstanding?

The sale of 59,900 shares represents about 0.11% of the disclosed 56,073,088 shares outstanding.

Who is the broker handling the sale in the SUPN Form 144?

The broker named is Morgan Stanley Smith Barney LLC, address listed as 1 New York Plaza, 8th Floor, New York, NY 10004.
Supernus Pharma

NASDAQ:SUPN

SUPN Rankings

SUPN Latest News

SUPN Latest SEC Filings

SUPN Stock Data

2.59B
54.88M
4.23%
109.56%
8.56%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
ROCKVILLE